By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive. 

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief. 

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial. 

New two-year findings, presented at TVT 2021, suggest that the Watchman FLX device is a safe alternative to long-term oral anticoagulation therapy.

The new analysis included data from nearly 700 patients who underwent TEER, formerly known as TMVR, over an eight-year period. 

Rather than a binary choice—atherectomy or lithotripsy—the market for treating severely calcified lesions seems likely to evolve into a mixture of both technologies. That, in fact, is already occurring. One strategy gaining currency among interventionalists, particularly those in Europe, is to try a high-pressure balloon first in cases of moderately severe calcification and, if the device fails to fully expand, re-enter the vessel with atherectomy. 

The study's authors emphasized how important it is for clinicians to work together to determine the best treatment strategy. 

Percutaneous edge-to-edge mitral valve repair was associated with improved outcomes among TAVR patients with persistent mitral regurgitation.